Abstract
Aims To review the role of cardiovascular disease and therapy in the onset and recurrence of preretinal/vitreous haemorrhage in diabetic patients.
Methods Retrospective case note analysis of diabetic patients with vitreous haemorrhage from the Diabetic Eye Clinic at Birmingham Heartlands Hospital.
Results In total, 54 patients (mean age 57.1, 37 males, 20 type I vs34 type II diabetic patients) were included. The mean (SD) duration of diagnosed diabetes at first vitreous haemorrhage was significantly longer, 21.9 (7.6) years for type I and 14.8 (9.3) years for type II diabetic patients (P<0.01, unpaired t-test, two-tailed).
Aspirin administration was not associated with a significantly later onset of vitreous haemorrhage. Four episodes were associated with ACE-inhibitor cough. There was a trend towards HMGCoA reductase inhibitor (statin) use being associated with a delayed onset of vitreous haemorrhage: 21.4 years until vitreous haemorrhage (treatment group) vs 16.2 years (nontreatment group) (P=0.09, two-tailed, unpaired t-test, not statistically significant).
During follow-up 56 recurrences occurred, making a total of 110 episodes of vitreous haemorrhage in 79 eyes of 54 patients. The mean (range) follow-up post haemorrhage was 1067 (77–3842) days, with an average of 1.02 recurrences. Age, gender, diabetes type (I or II) or control, presence of hypertension or hypercholesterolaemia, and macrovascular complications were not associated with a significant effect on the 1-year recurrence rate. Aspirin (and other antiplatelet or anticoagulant agents) and ACE- inhibitors appeared to neither increase nor decrease the 1-year recurrence rate. However, statin use was significantly associated with a reduction in recurrence (Fisher exact P<0.05; two-tailed) with an odds ratio (95% CI) of 0.25 (0.1–0.95).
Conclusion In this retrospective analysis, the onset of preretinal/vitreous haemorrhage was not found to be accelerated by gender, hypertension, hypercholesterolaemia, evidence of macrovascular disease, or HbA1c. Neither aspirin nor ACE-inhibitor administration accelerated the onset or recurrence of first vitreous haemorrhage. Statins may have a protective role, both delaying and reducing the recurrence of haemorrhage.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
DCCT Research group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. N Engl J Med 1993; 329: 977–986.
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352(9131): 837–853.
UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352(9131): 854–865.
Stratton IM, Kohner EM, Aldington SJ, Holman RR, Manley SE, Matthews DR . UKPDS50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. Diabetologia 2001; 44(2): 156–163.
UK Prospective Diabetes Study Group. UKPDS38: tight blood pressure control and risk of macrovascular and microvascular complications in type II diabetes. BMJ 1998; 317: 703–713.
Aiello LP, Cahill MT, Wong JS . Systemic considerations in the management of diabetic retinopathy. Am J Ophthalmol 2001; 132(5): 760–766.
Chowdhury TA, Hopkins D, Dodson PM, Vafidis GC . The role of serum lipids in exudative diabetic maculopathy: is there a place for lipid lowering therapy? Eye 2002; 16: 689–693.
Antiplatelet Trialists' Collaboration. Colloborative overview of randomised trials of antiplatelet therapy, I. Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81–106.
Cleland JGF . Preventing atherosclerotic events with aspirin. BMJ 2002; 324: 103–105.
Antiplatelet Trailists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. BMJ 2002; 324: 71–86.
Klein R, Marino EK, Kuller LH, Polak JF, Tracy RP, Gottdiener JS et al. The relation of atherosclerotic cardiovascular disease to retinopathy in people with diabetes in the Cardiovascular Health Study. Br J Ophthalmol 2002; 86: 84–90.
Chew EY, Klein ML, Murphy RP, Remaley NA, Ferris III FL . Effects of aspirin on vitreous/preretinal hemorrhage in patients with diabetes mellitus Early Treatment Diabetic Retinopathy Study Report No. Arch Ophthalmol 1995; 113: 52–55.
Kern TS, Engerman RL . Pharmacological inhibition of diabetic retinopathy; aminoguanidine and aspirin. Diabetes 2001; 50(7): 1636–1642.
Wood DA, Durrington P, McInnes G, Poulter N, Rees A, Wray R . Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 1998; 80 (Suppl 2): S1–S29.
Anderson KM, Odell PM, Wilson PW, Kammel WB . Cardiovascular disease risk profiles. Am Heart J 1991; 121: 293–298.
Al-Husainy S, Farmer J, Gibson JM, Dodson PM . Measurement of blood pressure in patients with diabetic retinopathy. Eye 2004 (in press).
Colhoun HM, Thomason MJ, Mackness MI, Maton SM, Betteridge DJ, Durrington PN et al. Collaborative AtoRvastatin Diabetes Study (CARDS). Design of the Collaborative AtoVastatin Diabetes Study (CARDS) in patients with type 2 diabetes. Diabet Med 2002; 19(3): 201–211.
Donaldson M, Dodson PM . Medical treatment of diabetic retinopathy. Eye 2003; 17: 550–562.
Author information
Authors and Affiliations
Corresponding author
Additional information
Conflict of interest: None
Presented in part at the International Congress of Ophthalmology, Sydney, April 2002 and the Annual Congress of Royal College of Ophthalmologists, Manchester, May 2002
Rights and permissions
About this article
Cite this article
Banerjee, S., Denniston, A., Gibson, J. et al. Does cardiovascular therapy affect the onset and recurrence of preretinal and vitreous haemorrhage in diabetic eye disease?. Eye 18, 821–825 (2004). https://doi.org/10.1038/sj.eye.6701338
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.eye.6701338
Keywords
This article is cited by
-
Management of Complications and Vision Loss from Proliferative Diabetic Retinopathy
Current Diabetes Reports (2021)
